08:00 , Feb 2, 2015 |  BioCentury  |  Emerging Company Profile

Three's company

Stimulants are the most effective drugs for ADHD, but the very things that make them effective - blocking norepinephrine and dopamine reuptake - can also lead to addiction and cause anxiety. Neurovance Inc.'s lead candidate...
07:00 , Jun 3, 2013 |  BC Week In Review  |  Clinical News

Amitifadine: Phase IIb/IIIa data

Top-line data from the double-blind, U.S. Phase IIb/IIIa TRIADE trial in 342 patients with MDD showed that once-daily 50 and 100 mg doses of amitifadine each missed the primary endpoint of improving MADRS score from...
07:00 , Oct 22, 2012 |  BC Week In Review  |  Clinical News

Amitifadine: Completed Phase IIb/IIIa enrollment

Euthymics completed enrollment of 342 patients in the placebo-controlled, double-blind, U.S. Phase IIb/IIIa TRIADE trial comparing 50 and 100 mg amitifadine vs. Paxil paroxetine for 12 weeks in patients with an inadequate response to...
07:00 , Oct 22, 2012 |  BioCentury  |  Finance

Maximizing depression

Maximizing depression Euthymics Bioscience Inc. thinks spinning out its early stage assets into Neurovance Inc. will make it easier to partner Euthymics' lone remaining asset - its amitifadine candidate for depression. The two companies will have the...
01:28 , Oct 19, 2012 |  BC Extra  |  Company News

Euthymics' Neurovance spinout raises $7M

Neurovance Inc. (Cambridge, Mass.) emerged Thursday as a spinout of Euthymics Bioscience Inc. (Cambridge, Mass.) with $7 million raised in a series A round. Existing Euthymics investors financed the Neurovance round, including lead investor Novartis...
08:00 , Dec 5, 2011 |  BioCentury  |  Emerging Company Profile

Euthymics: Balancing act

Euthymics Bioscience Inc. thinks a molecule orphaned by Dov Pharmaceutical Inc. has the right relative ratio of monoamine reuptake inhibition to offer better efficacy and tolerability than marketed antidepressants. About 60% of MDD patients fail a...
07:00 , Mar 21, 2011 |  BC Week In Review  |  Clinical News

EB-1010: Phase IIb/IIIa started

Euthymics began the placebo-controlled, double-blind, U.S. Phase IIb/IIIa TRIADE trial to compare 50 and 100 mg EB-1010 vs. Paxil paroxetine for 12 weeks in about 300 patients. Euthymics gained the compound through its reverse-merger...
08:00 , Dec 13, 2010 |  BC Week In Review  |  Clinical News

EB-1010: Phase II data

Data from the modified intent-to-treat (mITT) population (n=56) of a double-blind, U.S. and European Phase II trial showed that EB-1010 met the primary endpoint of significantly improving MADRS total score at week 6 vs. placebo...
00:10 , Dec 9, 2010 |  BC Extra  |  Clinical News

Euthymics' EB-1010 meets depression endpoint

Euthymics Bioscience Inc. (Cambridge, Mass.) said EB-1010 met the primary endpoint vs. placebo in a Phase II trial to treat major depressive disorder (MDD). In the modified intent-to-treat population of 56 patients, EB-1010 significantly improved...
07:00 , Jul 26, 2010 |  BioCentury  |  Finance

Bear out of Hibernation

Dov Pharmaceutical Inc. has been slowing dying for a long time, but its neglected assets are now back in play in newco Euthymics Bioscience Inc., which VCs financed with $24 million in a tranched series...